47 results about "Tumor pain" patented technology

The invention discloses a cancer pain treatment pain assessment method and system based on intelligent data processing, and relates to the field of treatment assessment, and the method comprises the steps: 1, obtaining basic pathological data, medication records and real-time vital signs of a patient in real time through a hospital information system, extracting symptom features, and carrying out the calculation of the symptom features; identifying the self-contained pain text of the patient, extracting the pain event characteristics, and matching the symptom with the pain event characteristics to form a pain correlation factor matrix; 2, constructing a pain prediction model based on a time sequence convolutional network, and generating a multi-dimensional data acquisition trigger instruction; a mode of combining a time sequence convolutional network and a multi-head self-attention mechanism is adopted, a high-sensitivity acquisition window of a pain event is automatically identified, discontinuous event interference is inhibited through a time decay factor, and a high-weight time period is reserved by utilizing sparsification, so that a data acquisition time period with a high contribution value is automatically obtained; and the recognition precision of the key pain time period is remarkably improved.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The utility model discloses a puncture surgical instrument device. The injection needle comprises a needle body, a needle sleeve is fixedly arranged on the outer side of the needle body, an injection hole and a laser optical fiber are arranged in the needle body, one end of the needle body is exposed out of the needle sleeve, and an optical fiber connector module is detachably and fixedly arranged at the other end of the needle body; the outer side of the needle body is electrically connected with equipment for generating current, and the laser optical fiber is electrically connected with the optical fiber connector module; a target tissue is electrically stimulated through the needle body, a nervous tissue is positioned, a target tissue inducing tumor pain is accurately found, after the target tissue is found, laser ablation is conducted on the target tissue by placing a laser optical fiber through a mounting hole, and finally, when medicine injection and water separation release need to be conducted on the target tissue, the target tissue is subjected to laser ablation. The liquid medicine can be conveyed to a target tissue through the injection hole; tedious operations such as repeated puncture injury and replacement of puncture needles are avoided, the possibility of tumor metastasis caused by surgical operation can be reduced while the surgical time is shortened, and original nerves are protected to the maximum extent.

Provided is a use of an oncolytic virus in the treatment of pain, especially in the treatment of cancer while relieving cancer pain. The drug effect time of the oncolytic virus for relieving cancer pain is obviously longer than that of the existing opioid analgesic, and the dual effects of treating cancer and easing pain are achieved at the same time.

The present invention relates to the process of enrichment of Phytocannabinoids namely CBD and Δ9-THC from the dried aerial part (leaves and inflorescence) of Cannabis sativa. The present invention also relates to the preparation of formulation having enriched CBD and THC by combining with appropriate acceptable excipients such as nutriose, dextrin and maltodextrin. The present invention also discloses the use of the phytocannabanoids enriched blend for the management of pain including cancer pain & general pain.

The present invention provides use of lncRNA XR_595534.2 in the preparation of a medicine for the treatment or prevention of chronic pain. In the present invention, trigeminal neuralgia induced by chronic constriction injury of infraorbital nerve in rats is used as a pain model. A specifically and differentially highly expressed long-chain non-coding RNA gene lncRNA XR_595534.2 is screened in the model. An interfering RNA targeting lncRNA XR_595534.2 is provided for disease treatment. The present invention discovers for the first time that lncRNA XR_595534.2, which is specifically and differentially highly expressed in a pain model, has significantly reduced expression by stereotactic injection of an interfering RNA to relieve the pain behavior, and is useful in the preparation of a medicine for the treatment or prevention of trigeminal neuralgia, neuropathic pain, migraine and cancer pain where lncRNA-XR595534.2 is a target.

The invention discloses oligopeptide and application thereof in preparation of a medicine for treating and / or relieving pain. The amino acid sequence of the oligopeptide disclosed by the invention comprises a derivative sequence formed by additionally arranging 1-3 amino acids at the N end and / or C end of the amino acid sequence shown as Tyr-Pro-Arg, especially Tyr-Pro-Arg-Arg (YPRR, YR4), and a gastrointestinal tract digestion product Tyr-Pro-Arg (YPR, YR3) of the oligopeptide. The oligopeptide not only can relieve acute pain induced by a mouse thermal drifting model, but also can relieve chronic pain induced by a rat sciatic nerve chronic compression injury model and a tibia bone cancer pain model, and meanwhile, the oligopeptide obviously inhibits CCI-induced spinal astrocyte, microglia and neuron activation; therefore, the compound has important development and application values in the aspects of central sensitization inhibition and analgesia.

The invention relates to the technical field of medicines, in particular to application of anwuligan in preparation of medicines for treating or preventing neuroinflammation related diseases and bone cancer pain. Animal experiments prove that the anwuligan can relieve nerve cell inflammatory response, inhibit tumor cell growth, prevent bone destruction caused by tumors and inhibit mechanical pain sensitivity, heat pain sensitivity and spontaneous pain of bone cancer pain rats. Results show that the anwuligan has potential anti-inflammatory, anti-cancer and analgesic effects and has an application prospect of being developed into a medicine for preventing and treating cancer pain.

The invention discloses application of Ryk-Fc fusion protein in preparation of anti-cancer pain drugs, and belongs to the technical field of biological medicines. The invention provides a new application of the Ryk-Fc fusion protein, the new application is an application of the Ryk-Fc fusion protein in preparation of drugs for treating cancer pain, the Ryk-Fc fusion protein realizes a function of treating cancer pain by inhibiting expression of TRPV1 protein in dorsal root node neurons, and the Ryk-Fc fusion protein has strong pertinence in a treatment process, has a remarkable treatment effect, and can be used for preparing drugs for treating cancer pain. Side effects are low. The invention provides a theoretical basis for research and development of drugs for treating cancer pain, and provides a feasible scheme for preparation of novel drugs for treating cancer pain.

The purpose of the present invention is to provide a prophylactic or therapeutic agent for cancer pain. The present invention provides a pharmaceutical composition for preventing or treating cancer pain, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In the formula (I), m is an integer of 1-4; r1 is independently selected from a group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted by 1-3 halogen atoms, a methoxy group optionally substituted by 1-3 halogen atoms, and a methylthio group optionally substituted by 1-3 halogen atoms.

This invention relates to the field of traditional Chinese medicine preparation technology, and particularly to a traditional Chinese medicine composition for treating cancer pain and numbness, as well as its preparation and application. This invention designs a traditional Chinese medicine composition for cancer pain and numbness, comprising: *Houttuynia cordata*, *Aconitum carmichaelii*, processed *Aconitum carmichaelii*, centipede, *Astragalus membranaceus*, *Ephedra sinica*, clove, frankincense, ephedra, menthol, and azone. The scientifically formulated combination of principal, assistant, and adjuvant herbs allows for multi-target action on both "cancer pain" (inflammation, compression, nerve infiltration) and "CIPN" (nerve damage), resulting in a superior analgesic effect, while also possessing anti-inflammatory, anti-swelling, potential tumor-suppressing, and nerve-repairing effects. The traditional Chinese medicine composition is prepared into a traditional Chinese medicine ointment, which is administered transdermally, allowing a high concentration of the drug to act directly on the lesion, avoiding the systemic side effects (addiction, constipation, etc.) associated with oral opioids. This is especially suitable for patients who cannot take oral opioids or cannot tolerate them.

The invention provides a method and system for establishing a cancer pain prognosis prediction model, and the method comprises the steps: collecting cases, and selecting variable factors which need to be included in the construction of the prediction model; detecting the genotype of each SNP site by adopting gene sequencing; assigning values to dependent variable factors and independent variable factors; a prediction model is established based on Logistic regression analysis; and evaluating the prediction capability of the prediction model by using the Cox-Snell R score and the Neigore R score. The prediction model is established by detecting genotype combination analysis of SNP loci with a great cancer pain prognosis effect and combining clinical characteristics, biochemical indexes and gene detection results, individual prediction is used for each patient, cancer pain patients with poor prognosis are found timely and accurately, the drug test time is shortened, the identification speed is increased, and the detection efficiency is improved. The efficiency of determining the treatment effect of the cancer pain medicine is improved, and insufficient analgesia and serious adverse reaction are avoided.

The application discloses a polypeptide targeting palmitoylation modification of APLNR protein and application thereof in cancer pain treatment, in particular, application of APLNR protein and a palmitoylation modification site of the APLNR protein in relieving morphine tolerance in treatment of cancer pain. It is found by the application that the palmitoylation modification of APLNR is one of important response factors of neuropathic cancer pain, and a polypeptide targeting palmitoylation modification of APLNR protein is developed by taking the APLNR protein as a target, and the polypeptide is combined with morphine to treat cancer pain, so that the cancer pain can be effectively reduced, and the occurrence of morphine tolerance can be relieved, thereby providing a new strategy for clinical treatment of cancer pain and relief of morphine tolerance.

Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and / or management of pain and related conditions, including post-operative pain, pain incident to an incision or wound, chronic pain, severe pain, moderate to severe chronic pain, or chronic non-cancer pain, the method comprising administering to the subject a therapeutically effective amount of a compound.

The invention discloses intelligent opioid medicine titration administration control equipment for cancer pain patients, which comprises a solid-state pump, a control panel and a working process of the control panel, and comprises the following steps: collecting real-time physiological data, and obtaining discrete data sequences of skin electrical activity, myoelectricity, respiratory rate, oxyhemoglobin saturation, heart rate and diastolic pressure; preprocessing the discrete data sequence to generate a time-index matrix; processing the time-index matrix by adopting a multi-scale morphological gradient algorithm, and extracting pain risk characteristics and metabolic influence characteristics; and processing the pain risk characteristics and the metabolic influence characteristics by adopting a multi-user orthogonal resource scheduling algorithm, and generating a control instruction containing the total dosage, the total time and the rate of the titration administration of the opioids of the solid-state pump. Therefore, key information related to pain and metabolic safety can be captured in a targeted mode, the individual state of a patient can be mastered more accurately, and the analgesic effect is optimized on the premise that medication safety is guaranteed.

The invention provides a tumor pain management system based on an artificial intelligence technology, and relates to the technical field of medical auxiliary management systems, and the system comprises a biosensing module which is used for real-time physiological and biochemical monitoring; the AI analysis module is used for analyzing the data of the biosensing module and providing analysis data; the personalized pain management module is used for performing terminal control on the analysis data of the AI analysis module; the doctor / patient interface is used for terminal control of doctors / patients; the data storage module is used for storing physiological and biochemical parameters, analysis results and pain management schemes of patients, and through cooperative work of the AI analysis module and the personalized pain management module, the system can formulate the personalized pain management schemes according to the physiological and biochemical parameters of each patient, and the pain management schemes are used for pain management. The personalized management mode can more effectively relieve the pain of the patient and improve the life quality of the patient.

The invention discloses a traditional Chinese medicine composition for treating cancer pain, a traditional Chinese medicine acupoint patch and a preparation method of the traditional Chinese medicine acupoint patch. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 60 parts of spina gleditsiae, 15 to 30 parts of rhizoma curcumae, 15 to 30 parts of rhizoma sparganii, 5 to 10 parts of rhizoma zingiberis, 10 to 20 parts of radix angelicae, 3 to 6 parts of flos carthami, 5 to 10 parts of ground beeltle, 5 to 10 parts of earthworm and 3 to 6 parts of radix notoginseng. The traditional Chinese medicine acupoint patch for treating cancer pain has the effects of promoting blood circulation to remove blood stasis, eliminating stagnation and eliminating mass, and activating meridians to stop pain, and is convenient to use and good in patient compliance.

Disclosed herein are compositions for and methods of treating, preventing, and / or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed herein are compositions for and methods of providing non-opioid analgesia in a subject in need thereof.

Disclosed is a method for relieving cancer pain in a patient. The method comprises administering a patch to a patient in need thereof, wherein the patch comprises a backing layer and an adhesive layer laminated on the backing layer, the adhesive layer comprises an adhesive base and 150 mg to 225 mg of diclofenac sodium, and wherein the patch is applied once a day.

The invention discloses an RVG29 modified ziconotide loaded liposome as well as a preparation method and application thereof. The nano-liposome is prepared from phosphatidylpolyethylene glycol-RVG29, lecithin, cholesterol, phosphatidic acid and ziconotide. The preparation method comprises the following steps: performing repeated washing, resin detection and condensation operation on 2-chlorotrityl chloride resin and the like to prepare RVG29 resin, performing cutting sedimentation treatment and high performance liquid chromatography purification on the RVG29 resin by using phospholipid-polyethylene glycol-active ester and a cutting reagent, and adding lecithin, cholesterol, phosphatidic acid and ziconotide to synthesize and prepare the product liposome. The nano-liposome is a novel nano-liposome for the nose and the brain, gel adhesion and drug delivery are improved, the surface of the liposome targets a nicotinic acetylcholine receptor on the surface of a neuron, accurate drug delivery is achieved, no small-molecule cytotoxic drugs participate in the nano-liposome, the treatment compliance of cancer pain patients is improved, and the nano-liposome is a novel nano-liposome for the nose and the brain. The treatment effect and the life quality are improved.

This invention relates to the field of medical and health information technology and discloses a home-based pain monitoring system for malignant tumor patients. The invention collects various data related to home care of malignant tumor patients, forming pain datasets, medication datasets, and vital sign datasets. Based on these three datasets, pain risk indices, medication risk indices, and vital sign risk indices are obtained. These are then weighted and summed to obtain a comprehensive risk index. Effective correlation and collaborative analysis of multi-dimensional data improve the accuracy of the comprehensive risk index. The system determines whether to issue an alert based on the comprehensive risk index. If the comprehensive risk index reaches a threshold, three different levels of alerts (red, orange, and yellow) are issued and sent to both the patient-side interaction module and the medical staff-side interaction module. Upon receiving the alert, medical staff immediately review the patient's current condition report, analyze it, and receive timely improvement suggestions to help the patient improve their current condition, thus improving the efficiency of home care.

The invention belongs to the technical field of medicine, and particularly relates to application of LXH-2103 in preparation of medicine for treating pain and medicine dependence and a medicine composition of the LXH-2103. According to the application of the LXH-2103 disclosed by the invention in pain, the pain is acute incision pain, osteoarthritis pain, sciatica and cancer pain. The intravenous injection dosage of the medicine in an acute incision pain model animal is 7.5-20 mg / kg, and the oral administration dosage of the medicine in gavage is 20 mg / kg. The injection dosage of the medicine for treating osteoarthritis pain and sciatica is 2.5-7.5 mg / kg, and the oral administration dosage of the medicine for gavage is 20 mg / kg. The injection dosage of the medicine for cancer pain is 3-12 mg / kg, and the oral administration dosage of the medicine for gavage is 30 mg / kg. According to the establishment of the LXH-2103 in the pain model and the application of the LXH-2103 in the pain, a plurality of pain animal models are established, and the application of the LXH-2103 in the pain treatment is evaluated.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine plaster formula targeting tumor acupoints and application of the traditional Chinese medicine plaster formula, the traditional Chinese medicine plaster formula is composed of 24 traditional Chinese medicines such as musk, oldenlandia diffusa and sculellaria barbata, the scheme deeply integrates traditional Chinese medicine transdermal absorption and meridian targeting tropism mechanisms, and the limitation that traditional external treatment neglects overall differentiation is broken through. According to the preparation process, through segmented treatment and low-temperature reaction, the sensitization risk of minium is remarkably reduced, the anti-tumor curative effect can be synergistically enhanced, cancer pain can be relieved, malignant effusion can be controlled, particularly, the dosage of western medicines can be reduced and toxic and side effects can be reduced when the medicine is combined with radiotherapy and chemotherapy, and a safe and effective adjuvant therapy means is provided for tumor patients.

The application discloses a painkilling preparation containing radix scophulariae and radix aconiti and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine. The preparation is a transdermal patch, which is composed of a backing layer, a drug depot layer and an anti-sticking layer. The drug depot layer contains traditional Chinese medicine active ingredients and patch auxiliaries such as pressure-sensitive adhesive and transdermal absorption accelerators. The traditional Chinese medicine active ingredients take radix scophulariae and radix aconiti as the core drug pair, and are supplemented with one or more of the following drugs: qi-regulating analgesic drugs, blood-removing qi-regulating drugs, blood-activating analgesic drugs, blood-stasis-removing analgesic drugs, warm-qi-activating cold-dispelling drugs, wind-dispelling cold-dispelling drugs and external analgesic drugs. The application is a modern traditional Chinese medicine external preparation prepared by a patch technology, and the drug can penetrate the skin and directly reach the lesion, thereby playing a therapeutic role on inflammatory pain, cancer pain and idiopathic pain. The preparation has the characteristics of large drug loading, good transdermal absorption, fast analgesic effect, long-acting effect and avoidance of oral toxicity risk.

The invention relates to the field of cancer pain analysis of human body images, in particular to a cancer pain treatment response evaluation method based on image analysis. The method comprises the steps of collecting continuous human body images of a patient; firstly, angular points in each image are collected; obtaining an angular point aggregation coefficient according to the distance characteristics between the angular points; uniformly dividing the image to obtain human body image layers; in the layering process, key angular points are obtained according to the angular point aggregation coefficient difference of the angular points; obtaining an activity coefficient according to similar features between the angular point aggregation coefficient difference and the key angular points; obtaining a response degree according to the activity coefficient; and performing response evaluation on cancer pain treatment according to the response degree of the patient. According to the invention, a non-invasive, real-time and quantitative cancer pain treatment dynamic evaluation method can be provided for the patient by dynamically tracking the activity characteristics of the patient.

The invention discloses a cancer pain patient intelligent portraying and accurate follow-up visit system based on a dynamic knowledge graph, and belongs to the technical field of medical informatization, artificial intelligence, knowledge graphs and accurate medical crossing, and the method comprises the following steps: 1, constructing a double-knowledge graph architecture comprising a medical knowledge graph and a follow-up visit question knowledge graph, wherein the medical knowledge graph covers entities such as cancer pain related diseases, drugs, symptoms and treatment schemes and association relationships, and a mapping relationship between questions and medical entities is established by the follow-up question knowledge graph; 2, accessing HIS / LIS system data, wearable device monitoring data, follow-up feedback data and other multi-source heterogeneous data, and performing cleaning, standardization and desensitization processing to complete multi-source data fusion; and 3, constructing a patient intelligent portrait containing six dimensions of pathology, pain, treatment, psychology, society and dynamic characteristics based on the fusion data, and storing and supporting real-time dynamic updating in a JSON format.

The invention discloses an application of isokaurenoic acid in preparation of a medicine for treating and / or preventing pain. The invention relates to an application of isokaurenoic acid in preparation of a medicine for treating and / or preventing pain. The pain comprises but not limited to inflammatory pain, neuropathic pain, cancer pain, postoperative pain and migraine. According to the present invention, the iso-kaurenoic acid is prepared into an oral drug, a mucosal drug or a dermatological drug for preventing and / or treating pain.

The utility model provides a cancer pain postoperative analgesia nursing device which comprises an analgesia device main machine and a manual controller, a connecting wire is installed between the analgesia device main machine and the manual controller, an anti-falling box is installed outside the connecting wire, the anti-falling box and the analgesia device main machine are detachably installed, and the anti-falling box is in threaded connection with a box cover. One side of the anti-drop box is provided with a wire inlet, and the other side of the anti-drop box is provided with a wire outlet. Due to the arrangement of the anti-falling box, the box cover, the wire inlet, the wire outlet, the vortex partition plate and the mounting hole, the connection strength of the manual controller and the analgesia pump main machine is improved, and the situation that when a user pulls the manual controller, a wire of the manual controller falls off from an insertion hole of the analgesia pump main machine is avoided.

The invention provides a new application of the polyphyllin VII, the polyphyllin VII can obviously inhibit the growth of tumor cells and effectively reduce the pain caused by tumor overgrowth, and by utilizing the effect of the polyphyllin VII for simultaneously inhibiting tumor growth and relieving cancer pain, and by virtue of the synergistic regulation of the polyphyllin VII on a'tumor immune microenvironment-inflammation-pain 'axis, the tumor immune microenvironment-inflammation-pain' axis can be inhibited, so that the tumor immune microenvironment-inflammation-pain pain can be inhibited, and the tumor immune microenvironment-inflammation-pain pain can be inhibited. The double effects of anti-tumor curative effect and cancer pain relieving are achieved, continuous treatment can relieve cancer pain and inhibit tumor growth, an effective scheme is provided for improving the life quality and autonomous activity of cancer patients, and important clinical significance and value are achieved.

The invention discloses a traditional Chinese medicine composition for treating cancer pain. The traditional Chinese medicine composition is prepared from, by weight, 30-70 parts of rhizoma corydalis, 30-70 parts of rhizoma corydalis decumbentis, 7-3 parts of radix curcumae, 7-3 parts of radix angelicae sinensis, 7-3 parts of radix salviae miltiorrhizae, 10-6 parts of frankincense, 10-6 parts of myrrh, 7-3 parts of radix bupleuri, 7-3 parts of fructus aurantii immaturus, 6-10 parts of radix paeoniae alba and 3-7 parts of radix glycyrrhizae. And 7-3 parts of rhizoma cyperi. The traditional Chinese medicine composition disclosed by the invention is researched and developed on the basis of diagnosis and treatment of cancer pain pathogenesis in traditional Chinese medicine, and has a good effect on treatment of cancer pain, particularly moderate pain and severe pain in late stage of cancer.